FORA Capital LLC acquired a new stake in Solventum Corporation (NYSE:SOLV – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 8,884 shares of the company’s stock, valued at approximately $676,000.
Other large investors have also added to or reduced their stakes in the company. Concurrent Investment Advisors LLC bought a new stake in Solventum in the 1st quarter valued at $216,000. Bessemer Group Inc. raised its stake in Solventum by 17.1% in the 1st quarter. Bessemer Group Inc. now owns 1,963 shares of the company’s stock valued at $150,000 after acquiring an additional 287 shares during the period. Perigon Wealth Management LLC raised its stake in Solventum by 3.8% in the 1st quarter. Perigon Wealth Management LLC now owns 4,352 shares of the company’s stock valued at $331,000 after acquiring an additional 159 shares during the period. Farther Finance Advisors LLC raised its stake in Solventum by 140.6% in the 1st quarter. Farther Finance Advisors LLC now owns 1,821 shares of the company’s stock valued at $139,000 after acquiring an additional 1,064 shares during the period. Finally, Amalgamated Bank raised its stake in Solventum by 1.3% in the 1st quarter. Amalgamated Bank now owns 27,120 shares of the company’s stock valued at $2,062,000 after acquiring an additional 352 shares during the period.
Solventum Stock Up 0.0%
Shares of NYSE SOLV opened at $72.94 on Thursday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. Solventum Corporation has a 52 week low of $59.35 and a 52 week high of $85.92. The stock has a market capitalization of $12.65 billion, a P/E ratio of 33.77, a PEG ratio of 1.77 and a beta of 0.52. The stock’s fifty day moving average is $73.77 and its 200 day moving average is $72.84.
Analyst Upgrades and Downgrades
SOLV has been the topic of a number of research analyst reports. Piper Sandler restated an “overweight” rating and issued a $94.00 price target (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th. Wells Fargo & Company increased their price target on Solventum from $75.00 to $79.00 and gave the company an “equal weight” rating in a research note on Friday, August 8th. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st. Finally, Wall Street Zen cut Solventum from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $85.75.
Get Our Latest Stock Analysis on SOLV
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Read More
- Five stocks we like better than Solventum
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Amazon’s Chart Just Flashed a Pennant Pattern—Here’s What to Do
- What is the Euro STOXX 50 Index?
- 3 Undervalued Stocks Analysts Are Loving Right Now—Should You?
- How Investors Can Find the Best Cheap Dividend Stocks
- Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.